How Analysts Feel About Loxo Oncology, Inc. (NASDAQ:LOXO)?

June 17, 2018 - By Winifred Garcia

Loxo Oncology, Inc. (NASDAQ:LOXO) LogoInvestors sentiment increased to 1.16 in Q1 2018. Its up 0.19, from 0.97 in 2017Q4. It improved, as 9 investors sold Loxo Oncology, Inc. shares while 53 reduced holdings. 32 funds opened positions while 40 raised stakes. 30.09 million shares or 75.89% less from 124.82 million shares in 2017Q4 were reported.
Franklin Resources invested in 246,520 shares. Awm Inv Com Inc accumulated 1.89% or 85,000 shares. Teacher Retirement Systems Of Texas stated it has 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Mackay Shields Limited Liability Corp holds 0.01% of its portfolio in Loxo Oncology, Inc. (NASDAQ:LOXO) for 8,600 shares. 17,590 were accumulated by Aqr Capital Mngmt Ltd. Parametric Portfolio Ltd Llc reported 23,479 shares or 0% of all its holdings. Nuveen Asset Management Llc has invested 0% in Loxo Oncology, Inc. (NASDAQ:LOXO). Ubs Asset Management Americas holds 0% in Loxo Oncology, Inc. (NASDAQ:LOXO) or 199,208 shares. Boothbay Fund Management Lc stated it has 0.08% in Loxo Oncology, Inc. (NASDAQ:LOXO). State Street reported 0.01% stake. State Of Wisconsin Invest Board stated it has 22,400 shares or 0.01% of all its holdings. 59,900 were accumulated by Quantitative Investment Management. Fmr invested in 4.33M shares or 0.06% of the stock. Rock Springs Capital Mgmt Limited Partnership invested in 316,500 shares or 1.56% of the stock. Aisling Cap Ltd Liability Co reported 70.71% in Loxo Oncology, Inc. (NASDAQ:LOXO).

Since December 19, 2017, it had 0 insider buys, and 20 sales for $24.63 million activity. $1.80 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by MAYLEBEN TIMOTHY M on Friday, June 8. $1.97 million worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Bilenker Joshua H.. Van Naarden Jacob had sold 3,082 shares worth $296,912 on Monday, February 12. 5,000 Loxo Oncology, Inc. (NASDAQ:LOXO) shares with value of $663,378 were sold by Kunkel Lori Anne. On Tuesday, December 19 the insider AISLING CAPITAL III LP sold $20.13M. $1.50M worth of Loxo Oncology, Inc. (NASDAQ:LOXO) was sold by Naider Avi Z..

Loxo Oncology, Inc. (NASDAQ:LOXO) Ratings Coverage

Among 10 analysts covering Loxo Oncology (NASDAQ:LOXO), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Loxo Oncology had 15 analyst reports since December 20, 2017 according to SRatingsIntel. The rating was maintained by JMP Securities with “Market Outperform” on Monday, June 4. The company was maintained on Wednesday, May 9 by Stifel Nicolaus. The firm has “Buy” rating given on Monday, June 4 by Stifel Nicolaus. Stifel Nicolaus maintained Loxo Oncology, Inc. (NASDAQ:LOXO) on Thursday, March 1 with “Buy” rating. On Monday, April 16 the stock rating was upgraded by Morgan Stanley to “Overweight”. The firm earned “Buy” rating on Thursday, February 22 by Oppenheimer. Citigroup maintained it with “Buy” rating and $151 target in Monday, March 5 report. The firm earned “Buy” rating on Wednesday, May 30 by Piper Jaffray. The stock has “Buy” rating by BTIG Research on Wednesday, December 20. As per Thursday, May 17, the company rating was maintained by Stifel Nicolaus. Below is a list of Loxo Oncology, Inc. (NASDAQ:LOXO) latest ratings and price target changes.

05/06/2018 Broker: IFS Securities Old Rating: Strong Buy New Rating: Market Perform Downgrade
04/06/2018 Broker: JMP Securities Old Rating: Market Outperform New Rating: Market Outperform Old Target: $182 New Target: $221 Maintain
04/06/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Overweight Old Target: $170 New Target: $215 Maintain
04/06/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $190 New Target: $225 Maintain
31/05/2018 Broker: PiperJaffray Rating: Overweight New Target: $200 Initiates Coverage On
30/05/2018 Broker: Piper Jaffray Rating: Buy New Target: $200.0000 Initiate
17/05/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $145 New Target: $190 Maintain
09/05/2018 Broker: Stifel Nicolaus Old Rating: Buy New Rating: Buy Old Target: $135 New Target: $145 Maintain
16/04/2018 Broker: William Blair Rating: Buy
16/04/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade

The stock decreased 1.11% or $1.99 during the last trading session, reaching $176.93. About 888,211 shares traded or 72.11% up from the average. Loxo Oncology, Inc. (NASDAQ:LOXO) has risen 248.86% since June 17, 2017 and is uptrending. It has outperformed by 236.29% the S&P500.

Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. The company has market cap of $5.32 billion. The Company’s lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase , which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. It currently has negative earnings. The companyÂ’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains.

More notable recent Loxo Oncology, Inc. (NASDAQ:LOXO) news were published by: Nasdaq.com which released: “New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star …” on June 07, 2018, also Seekingalpha.com with their article: “Financial Exchange Stock Talk: Joe McCann On Loxo Oncology” published on May 29, 2018, Nasdaq.com published: “Loxo Oncology Announces Positive Interim Clinical Data from LOXO-292 Dose Escalation Trial in RET-Altered Cancers …” on June 02, 2018. More interesting news about Loxo Oncology, Inc. (NASDAQ:LOXO) were released by: Globenewswire.com and their article: “FDA Accepts Larotrectinib New Drug Application and Grants Priority Review” published on May 29, 2018 as well as Benzinga.com‘s news article titled: “Loxo Oncology’s Candidates Are ‘Impressive,’ Piper Jaffray Says In Bullish Initiation” with publication date: May 31, 2018.

Loxo Oncology, Inc. (NASDAQ:LOXO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.